Information about Prostate Cancer Screening
Prostate cancer is the most common non-skin cancer in men—with incidence rising as men age—but it does not behave the same way in every patient. Some prostate cancers grow very slowly and may never cause harm, while others can grow more quickly, spread to other parts of the body, and should be addressed without delay.
Importantly, prostate cancer often causes no symptoms, particularly in its early stages. Many men with prostate cancer feel completely well and may never notice any physical changes at all. Because symptoms are often absent—or appear only later—clinicians cannot rely on how a man feels to determine whether prostate cancer may be present.
For this reason, prostate cancer screening focuses on identifying biological signals that cancer may be present before symptoms occur. Screening is not designed to diagnose cancer or determine how aggressive it might be. Instead, it helps identify men who would benefit from more precise testing or a closer evaluation.
Understanding the purpose and limitations of screening can help patients approach results with a clear perspective and avoid unnecessary worry or rushed decisions.
What Screening Is—and What It’s Not
Screening looks for early signs of disease in men who feel well. In prostate cancer, screening tools are used to identify changes that may warrant closer attention.
It is equally important to understand what screening does not do:
- It does not diagnose cancer; a biopsy remains the definitive way to confirm if cancer is present
- It does not determine whether a cancer is slow-growing or aggressive—this requires further testing, such as a prostate biopsy.
- It does not automatically lead to treatment
Screening is best viewed as the starting point of a thoughtful process, not the final answer.
Common Screening Tools for Prostate Cancer
In the United States, prostate cancer screening has traditionally involved one or both of the following tools:
Digital Rectal Exam (DRE)
A digital rectal exam involves a clinician examining the prostate with a gloved finger to feel for abnormalities in size, shape, or texture.
While DRE can detect prostate abnormalities, its use in routine screening has declined over time. Today, it is performed more selectively, by a specialist like a urologist, and often in combination with other information rather than as a primary screening tool on its own.
PSA Blood Test
The PSA (prostate-specific antigen) blood test is the most common screening tool for prostate cancer today.
PSA is a protein produced by the prostate and small amounts normally circulate in the bloodstream. When PSA levels are higher than expected, it can indicate that something is affecting the prostate, though not necessarily that cancer is present.
Because PSA screening plays a central role in prostate cancer detection, it is helpful to understand what PSA results can—and cannot—tell you.
Understanding the PSA Blood Test
PSA is not a cancer-specific marker. PSA levels can rise for many reasons unrelated to cancer, including:
- Benign (non-cancerous) prostate enlargement (also known as BPH)
- Inflammation or infection of the prostate
- Recent ejaculation or prostate stimulation
- Intense exercise that may stimulate the pelvis (such as long-distance cycling)
- Normal age-related changes
As a result, an elevated PSA does not automatically mean that prostate cancer is present—it simply means further investigation is needed to find the cause.
PSA as a Signal, Not a Diagnosis
PSA is a blood biomarker that acts as a signal that something may be happening in the prostate.
An elevated PSA may suggest that additional information could be helpful, but it does not answer critical questions on its own:
- Is cancer present?
- If cancer is present, how might it behave?
Indolent cancer: slow growing, doesn’t spread beyond the prostate, may never impact your health.
Aggressive cancer: fast-growing, can spread to other parts of the body, and may pose a serious health risk if not identified early and appropriately addressed.
Many men with elevated PSA levels do not have prostate cancer. Others may have prostate cancer that is unlikely to ever cause harm. PSA alone cannot distinguish between these situations.
What an Elevated PSA Really Means
Being told that your PSA is “elevated,” “high,” or “abnormal” can be unsettling. Without context, these terms can be misleading.
An elevated PSA generally means:
- Further evaluation may be appropriate
- Additional information is often needed before decisions are made
- Immediate action is not always required
In many cases, clinicians may:
- Repeat the PSA test
- Evaluate PSA trends over time (often called PSA velocity)
- Consider age, prostate size, family history, and overall health
Careful interpretation helps avoid undue anxiety and unnecessary procedures. By looking at the broader context—including using more specialized, precise diagnostic tools where appropriate—you and your clinician can get a much clearer picture of what an elevated PSA actually means for your health.
How Prostate Cancer Screening Has Evolved
In the past, elevated PSA levels often led directly to prostate biopsy. Over time, clinicians learned that this approach resulted in:
- Detection of prostate cancers unlikely to cause harm
- Treatments with meaningful side effects that can impact daily quality of life
- Increased stress without clear benefit
As understanding of prostate cancer improved, screening strategies evolved. Today’s approach emphasizes:
- Gathering more precise information before moving toward more invasive testing
- Identifying men more likely to benefit from further evaluation
- Supporting personalized, shared decision-making between patients and their clinicians
This evolution reflects a broader shift toward using screening results as guidance rather than directives.
When Screening Leads to Next Steps
For many men, screening results are reassuring and require no immediate follow-up beyond routine monitoring. For others, screening could suggest that additional information can help clarify the potential presence of cancer and whether it is likely to be slow-growing or aggressive. It means that the initial signal deserves a closer look.
At this stage, the focus shifts from detecting a signal to understanding what that signal is most likely to represent.
What Comes Next
When screening suggests that further evaluation may be helpful, clinicians may recommend tools designed to estimate the probability of finding aggressive prostate cancer, using additional biological and clinical information.
These tools aim to:
- Distinguish between situations that can be safely monitored while limiting additional invasive procedures
- Identify cases where taking action may be appropriate
- Support informed discussions between patients and clinicians